Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Nassau
    4. ›
  4. 11735
    5. ›
  5. CODAGENIX INC.

CODAGENIX INC.

Company claim

Is this your business?

Get access!

Company Details

Name: CODAGENIX INC.
Jurisdiction: New York
Legal type: FOREIGN BUSINESS CORPORATION
Status: Active
Date of registration: 01 Apr 2009 (16 years ago)
Entity Number: 3793440
ZIP code: 11735
County: Nassau
Place of Formation: Delaware
Address: 3 BIOSCIENCE PARK DRIVE, FARMINGDALE, NY, United States, 11735

DOS Process Agent

Name Role Address
CODAGENIX INC. DOS Process Agent 3 BIOSCIENCE PARK DRIVE, FARMINGDALE, NY, United States, 11735

Chief Executive Officer

Name Role Address
JOHN ROBERT COLEMAN Chief Executive Officer 3 BIOSCIENCE PARK DRIVE, FARMINGDALE, NY, United States, 11735

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Website:
www.codagenix.com
E-Commerce Website:
http://www.codagenix.com
Phone Number:
484-358-6843
E-mail Address:
jfu@codagenix.com
Contact Person:
JEFFREY FU
User ID:
P1058043

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
5D8K5
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-09-16
CAGE Expiration:
2029-09-16
SAM Expiration:
2025-09-12

Contact Information

POC:
JEFFREY FU
Corporate URL:
www.codagenix.com

History

Start date End date Type Value
2023-04-06 2023-04-06 Address 3 BIOSCIENCE PARK DRIVE, FARMINGDALE, NY, 11735, USA (Type of address: Chief Executive Officer)
2021-04-27 2023-04-06 Address 3 BIOSCIENCE PARK DRIVE, FARMINGDALE, NY, 11735, USA (Type of address: Service of Process)
2020-11-16 2023-04-06 Address 3 BIOSCIENCE PARK DRIVE, FARMINGDALE, NY, 11735, USA (Type of address: Chief Executive Officer)
2020-01-07 2020-11-16 Address 3 BIOSCIENCE PARK DRIVE, FARMINGDALE, NY, 11735, USA (Type of address: Principal Executive Office)
2011-05-09 2020-01-07 Address 7 GAY DRIVE, GREAT NECK, NY, 11024, USA (Type of address: Principal Executive Office)

Filings

Filing Number Date Filed Type Effective Date
230406000507 2023-04-06 BIENNIAL STATEMENT 2023-04-01
211220000851 2021-12-20 BIENNIAL STATEMENT 2021-12-20
210427000210 2021-04-27 CERTIFICATE OF CHANGE 2021-04-27
201116002020 2020-11-16 AMENDMENT TO BIENNIAL STATEMENT 2019-04-01
200107061151 2020-01-07 BIENNIAL STATEMENT 2019-04-01

USAspending Awards / Contracts

Procurement Instrument Identifier:
75A50123C00048
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DEFINITIVE CONTRACT
Action Obligation:
0.00
Base And Exercised Options Value:
0.00
Base And All Options Value:
0.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2023-09-30
Description:
CONDUCT A PHASE 2B EFFICACY STUDY AS PRESCRIBED IN AOI15 WITH COVILIV A PROPRIETARY LIVE ATTENUATED VIRUS COVID-19 VACCINE.
Naics Code:
541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Product Or Service Code:
AN42: HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH
Procurement Instrument Identifier:
W81XWH19C0051
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DEFINITIVE CONTRACT
Action Obligation:
451256.69
Base And Exercised Options Value:
947584.12
Base And All Options Value:
947584.12
Awarding Agency Name:
Department of Defense
Performance Start Date:
2019-04-15
Description:
ARMY 17.1 SBIR PHASE II MEDICAL R&D CONTRACT FOR PROPOSAL #A2-7469, TITLED "DEVELOPMENT OF A FLEXIBLE, LIVE TETRAVALENT DENGUE VACCINE" ERMS18263006
Naics Code:
541715: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
Product Or Service Code:
AN91: R&D- MEDICAL: OTHER (BASIC RESEARCH)
Procurement Instrument Identifier:
W81XWH18C0046
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DEFINITIVE CONTRACT
Action Obligation:
99991.59
Base And Exercised Options Value:
99991.59
Base And All Options Value:
148851.02
Awarding Agency Name:
Department of Defense
Performance Start Date:
2017-11-20
Description:
IGF::OT::IGF ARMY SBIR PH I PROPOSAL A171-067-0379 DEVELOPMENT OF A BALANCED AND EFFICACIOUS LIVE-ATTENUATED TETRAVALENT DENGUE VACCINE ERMS17152008
Naics Code:
541715: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
Product Or Service Code:
AN91: R&D- MEDICAL: OTHER (BASIC RESEARCH)

USAspending Awards / Financial Assistance

Date:
2023-09-27
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
GMP MANUFACTURING AND INITIAL CLINICAL EVALUATION OF A TETRAVALENT LIVE ATTENUATED DENGUE VACCINE. ADMIN MOD TO UPDATE THE AIMS OF THE SOW IN THE AWARD.
Obligated Amount:
5880000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-05-19
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
PRECLINICAL DEVELOPMENT OF A BALANCED, TETRAVALENT, LIVE-ATTENUATED VACCINE AGAINST THE FOUR DENGUE VIRUS SEROTYPES CHANGE OF PI ACQUISITION ACTIVITY (USAMRAA), US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USAMRDC) TRANSFERRED TO THE DEFENSE HEALTH AGENCY (DHA) FROM THE U.S. ARMY EFFECTIVE 01 OCTOBER 2022. THIS MODIFICATION REFLECTS CHANGES CONSISTENT WITH THE TRANSFER TO DHA. 2. DIVISION II (SEE ITEM # 13 ELECTRONIC PAYMENT INSTRUCTIONS) HAS BEEN UPDATED TO SUPERSEDE DIVISION III, SUBDIVISION B, PARAGRAPH 18
Obligated Amount:
0.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2022-09-19
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
1. UPDATES RECIPIENT BUSINESS OFFICIAL INFORMATION, PER THE EMAIL DATED 4 AUGUST 2022.2. UPDATES EMAIL ADDRESSES FOR THE GRANTS MANAGEMENT SPECIALIST AND GRANTS OFFICER IS REPRESENTATIVE.3. UPDATES THE FUNDING OVERVIEW TABLE.
Obligated Amount:
4443543.88
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-12-05
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
FINAL PRECLINICAL TESTING AND FORMULATION OF A SCALABLE, LIVE-ATTENUATED SARS-COV-2 VACCINE - PROJECT SUMMARY THERE IS A CRITICAL NEED FOR EFFECTIVE SARS-COV-2 VACCINES THAT CAN BE RAPIDLY PRODUCED AT LARGE SCALE. GIVEN OUR RUDIMENTARY UNDERSTANDING OF THE IMMUNOLOGICAL RESPONSES TO THE VIRUS, A VACCINE THAT ENGENDERS A BROAD-BASED RESPONSE (INNATE, HUMORAL, AND CELLULAR), IS PARTICULARLY APPEALING. FURTHER, WITH LITTLE OR NO A PRIORI KNOWLEDGE OF KEY IMMUNOLOGICAL TARGETS, A VACCINE THAT CAN PRESENT ALL OF A VIRUS’ ANTIGENS TO THE HOST IS IDEAL. IN RESPONSE, USING ITS UNIQUE COMPUTATIONAL ALGORITHM, CODAGENIX HAS DESIGNED AND COMPLETED INITIAL PRE-CLINICAL TESTING OF AN INTRANASAL, LIVE-ATTENUATED SARS-COV-2 VACCINE, CDX-005, THAT 1) ACTIVATES INNATE, HUMORAL, AND CELLULAR IMMUNE RESPONSES, 2) PRESENTS EVERY VIRAL ANTIGEN IN ITS NATURAL CONFORMATION TO THE INOCULATED HOST, AND 3) WILL BE INEXPENSIVE, FAST, AND EASY TO PRODUCE AT SCALE. THIS IS THE ONLY LAV BEING DEVELOPED FOR THE US MARKET. THE VACCINE GROWS ROBUSTLY IN FULLY CHARACTERIZED GMP CELLS AND PRE-CLINICAL DATA SUGGEST THAT A SINGLE, LOW, INTRANASAL DOSE IN THE RANGE OF 104-106 PFU WILL BE PROTECTIVE. PRE-CLINICAL TESTING IN SYRIAN GOLDEN HAMSTERS DEMONSTRATED THE SAFETY, ATTENUATION, AND EFFICACY OF CDX-005 IN VIVO, AND A PHASE I CLINICAL TRIAL WILL BE BEGINNING IN THE UK IN 2020 USING PRODUCT MANUFACTURED OVERSEAS. OUR GOAL IS TO PRODUCE AND DISTRIBUTE THE CDX-005 SARS-COV-2 VACCINE IN THE UNITED STATES. TO THIS END, CODAGENIX HAS HAD PRE-IND COMMUNICATIONS WITH AND GUIDANCE FROM THE FDA. WE PROPOSE TO COMPLETE ADDITIONAL PRE- CLINICAL STUDIES IN RESPONSE TO FDA RECOMMENDATIONS AND TO DEVELOP A FORMULATION THAT IS STABLE FOR EXTENDED PERIODS AT 4°C TO REDUCE SHIPPING COSTS, SIMPLIFY END-USER STORAGE, AND MAKE IT EASIER TO ADMINISTER THE VACCINE. ACCORDINGLY, IN AIM 1, WE WILL DEVELOP A CDX-005 FORMULATION THAT IS STABLE FOR EXTENDED PERIODS AT 2°-8°C. STARTING WITH OUR FROZEN FORMULATION AS A BASE, WE WILL TEST EXCIPIENTS FOR THEIR ABILITY TO STABILIZE A LIQUID VACCINE USING FORCED DEGRADATION, ACCELERATED STABILITY TESTING, AND LONG-TERM STABILITY TESTING PROTOCOLS. IN AIM 2, WE WILL DETERMINE THE TOXICITY, IMMUNOGENICITY, BIODISTRIBUTION, ATTENUATION, AND EFFICACY OF LATE PASSAGE CDX-005 IN SYRIAN GOLDEN HAMSTERS. IN PREPARATION FOR AN IND FILING, WE WILL 1) ASSESS TOXICITY BY HISTOPATHOLOGY AND HEMATOLOGY AFTER INOCULATION WITH CDX-005, 2) EXAMINE CDX-005 IMMUNOGENICITY BY SERUM IGG ELISA, PLAQUE REDUCTION NEUTRALIZATION, AND TH1/TH2 RESPONSE BY QPCR, 3) DETERMINE CDX-005 BIODISTRIBUTION AND ATTENUATION BY QPCR AND TCID50 IN TISSUES AND EXCRETIONS, AND 4) ASSESS CDX-005 EFFICACY BY SARS-COV-2 CHALLENGE. IN PARALLEL WITH THE PROPOSED WORK, WE WILL BRING CDX-005 MANUFACTURING CAPABILITIES TO THE US, CONDUCT A PHASE I CLINICAL TRIAL IN THE UK, AND SEQUENCE THE VIRUS FROM TISSUES IN THESE PATIENTS TO TEST FOR POSSIBLE REVERSION. WE RECOGNIZE THAT OTHER SARS-COV-2 VACCINES MAY REACH THE MARKET BEFORE CDX-005. WHILE THESE WILL BE A TREMENDOUS BOON SHORT TERM IN THE FIGHT AGAINST SARS-COV-2, THE ARE EXPECTED TO BE ONLY PARTIALLY PROTECTIVE. IN CONTRAST, WE ANTICIPATE THAT CDX-005, AS AN LAV, WILL PROVIDE A MUCH MORE ROBUST AND LONGER LASTING PROTECTION MAKING IT A MORE ATTRACTIVE CHOICE IN THE LONG TERM MARKET.
Obligated Amount:
0.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2017-08-22
Link:
View on USAspending
Awarding Agency Name:
Department of Agriculture
Transaction Description:
COMMERCIALIZATION OF A SYNTHETIC, TRI-VALENT LIVE-ATTENUATED SWINE-INFLUENZA VACCINE
Obligated Amount:
592912.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks Section

Serial Number:
90379509
Mark:
CODALYTIC
Status:
FIFTH EXTENSION - GRANTED
Mark Type:
TRADEMARK
Application Filing Date:
2020-12-14
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
CODALYTIC
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer
International Classes:
005 - Primary Class
Class Status:
Active
Serial Number:
90321852
Mark:
CODAGENIX
Status:
REGISTERED
Mark Type:
TRADEMARK, SERVICE MARK
Application Filing Date:
2020-11-16
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
CODAGENIX
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Vaccines; pharmaceutical products for the treatment of cancer; biologicals being biological preparations for the treatment of cancer
International Classes:
005 - Primary Class
Class Status:
Active
For:
Cancer therapies and treatments being medical cancer treatments and physical therapy for cancer patients
International Classes:
044 - Primary Class
Class Status:
Active
For:
Research and development of vaccines, medicines, and medical treatments; scientific and medical research and development
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
90181382
Mark:
CODAVAX
Status:
ABANDONED - NO STATEMENT OF USE FILED
Mark Type:
TRADEMARK
Application Filing Date:
2020-09-15
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
CODAVAX
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Vaccines
International Classes:
005 - Primary Class
Class Status:
Active
Serial Number:
97559765
Status:
FOURTH EXTENSION - GRANTED
Mark Type:
TRADEMARK, SERVICE MARK
Application Filing Date:
2022-08-23
Mark Drawing Type:
Illustration: Drawing or design without any word(s)/letter(s)/number(s)
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Vaccines; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; biologicals being biological preparations for the treatment of cancer
International Classes:
005 - Primary Class
Class Status:
Active
For:
Cancer therapies and treatments being medical cancer treatments and physical therapy for cancer patients
International Classes:
044 - Primary Class
Class Status:
Active
For:
Research and development of vaccines, medicines, and medical treatments; scientific and medical research and development
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
97221377
Mark:
COVILIV
Status:
FOURTH EXTENSION - GRANTED
Mark Type:
TRADEMARK
Application Filing Date:
2022-01-15
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
COVILIV
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Vaccines; pharmaceutical products for the treatment of viral and infectious diseases
International Classes:
005 - Primary Class
Class Status:
Active

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

No related officers

Related by address

No related companies by address

Date of last update: 27 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated